Citius Oncology (CTOR) Competitors

Citius Oncology (NASDAQ:CTOR) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Does the media favor CTOR or AVIR?

In the previous week, Atea Pharmaceuticals had 6 more articles in the media than Citius Oncology. MarketBeat recorded 9 mentions for Atea Pharmaceuticals and 3 mentions for Citius Oncology. Atea Pharmaceuticals' average media sentiment score of 0.52 beat Citius Oncology's score of -1.00 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Atea Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals have more ownership in CTOR or AVIR?

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 4.6% of Citius Oncology shares are held by company insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is CTOR or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -34.90% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-43.67%	-9.74%
Atea Pharmaceuticals	N/A	-34.90%	-32.38%

Do analysts prefer CTOR or AVIR?

Citius Oncology currently has a consensus target price of $3.00, indicating a potential upside of 227.87%. Atea Pharmaceuticals has a consensus target price of $6.00, indicating a potential upside of 118.98%. Given Citius Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Citius Oncology is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Atea Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community believe in CTOR or AVIR?

Atea Pharmaceuticals received 18 more outperform votes than Citius Oncology when rated by MarketBeat users. However, 100.00% of users gave Citius Oncology an outperform vote while only 47.50% of users gave Atea Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Citius Oncology	Outperform Votes 1 100.00%	Underperform Votes No Votes
Atea Pharmaceuticals	Outperform Votes 19 47.50%	Underperform Votes 21 52.50%

Which has more risk and volatility, CTOR or AVIR?

Citius Oncology has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

Which has stronger valuation & earnings, CTOR or AVIR?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$21.15M	N/A	N/A
Atea Pharmaceuticals	N/A	N/A	-$135.96M	-$1.65	-1.66

Summary

Atea Pharmaceuticals beats Citius Oncology on 7 of the 12 factors compared between the two stocks.